产品名称

英文名称：LY2228820

同义词

862507-23-1、LY2228820、Ralimetinib Mesylate、Ralimetinib dimesylate、LY2228820 diMesylate、Ralimetinib mesilate、Ralimetinib mesylate [USAN]、862507-23-1 (mesylate)、5-(2-(tert-butyl)-4-(4-fluorophenyl)-1H-imidazol-5-yl)-3-neopentyl-3H-imidazo[4,5-b]pyridin-2-am

产品性质

CAS编号：862507-23-1

分子式：C26H37FN6O6S2

分子量：612.74

PubChem编号：11570805

英文别名：862507-23-1|LY2228820|Ralimetinib Mesylate|Ralimetinib dimesylate|LY2228820 diMesylate|Ralimetinib mesilate|Ralimetinib mesylate [USAN]|862507-23-1 (mesylate)|5-(2-(tert-butyl)-4-(4-fluorophenyl)-1H-imidazol-5-yl)-3-neopentyl-3H-imidazo[4,5-b]pyridin-2-am

规格或纯度：≥98%

英文名称：LY2228820

生化机理：SB 202190 is a p38 MAP (mitogen activated protein) Kinase inhibitor with an IC50 of 7 nm. LY2228820 inhibits lipopolysaccharide (LPS)-induced TNFα formation in murine peritoneal macrophages, with IC50 of 5.2 nM. In multiple myeloma (MM) cells, LY2228820 significantly blocks p38MAPK signaling, as revealed by its inhibition on phosphorylation of HSP27, a downstream target of p38MAPK, without affecting the expression level of HSP27. LY2228820 enhances bortezomib-induced cytotoxicity and apoptosis, but it alone doesn't inhibit the growth of MM.1S cells. LY2228820 also inhibits secretion of IL-6 and MIP-1α in long-term BM stromal cells (LT-BMSCs), BM mononuclear cells (BMMNCs), peripheral blood (PB) CD138+, CD138? or PB CD14+ cells. LY2228820 also blocks osteoclastogenesis from CD14+ cells.LY 2228820 is a novel and potent p38 MAPK inhibitor with potent anti-inflammatory activity.\xa0It significantly inhibited phosphorylation of MAPKAPK2 and/or HSP27, down stream targets of p38MAPK, in both multiple myeloma (MM) cell lines and LT-BMSCs.

储存温度：-20°C储存

运输条件：超低温冰袋运输

备注：如果有可能，您尽量在使用的当天配置溶液，并在当天使用完它。但是，如果您需要预先配制储备溶液，我们建议您将溶液等份保存在-20°C的密封小瓶中。通常，它们最多可以使用一个月。在使用前和打开样品瓶之前，我们建议您让您的产品在室温下平衡至少1小时。需要更多关于溶解度，用法和处理的建议吗？请访问我们的常见问题（FAQ）页面以获取更多详细信息。

产品介绍：LY2228820是p38MAPK抑制剂，对p38αMAPK和p38βMAPK的IC50分别为7 nM和3 nM。A p38 MAP Kinase inhibitor with IC50 of 70nMLY2228820 is a novel and potent inhibitor of p38 MAPK with IC50 of 7 nM in a cell-free assay, does not alter p38 MAPK activation.A p38 MAP Kinase inhibitor with IC50 of 70nM

IUPAC Name：5-[2-tert-butyl-4-(4-fluorophenyl)-1H-imidazol-5-yl]-3-(2,2-dimethylpropyl)imidazo[4,5-b]pyridin-2-amine;methanesulfonic acid

INCHI：InChI=1S/C24H29FN6.2CH4O3S/c1-23(2,3)13-31-20-17(28-22(31)26)12-11-16(27-20)19-18(14-7-9-15(25)10-8-14)29-21(30-19)24(4,5)6;2*1-5(2,3)4/h7-12H,13H2,1-6H3,(H2,26,28)(H,29,30);2*1H3,(H,2,3,4)

InChi Key：NARMJPIBAXVUIE-UHFFFAOYSA-N

Canonical SMILES：CC(C)(C)CN1C2=C(C=CC(=N2)C3=C(N=C(N3)C(C)(C)C)C4=CC=C(C=C4)F)N=C1N.CS(=O)(=O)O.CS(=O)(=O)O

Isomeric SMILES：CC(C)(C)CN1C2=C(C=CC(=N2)C3=C(N=C(N3)C(C)(C)C)C4=CC=C(C=C4)F)N=C1N.CS(=O)(=O)O.CS(=O)(=O)O

PubChem CID：11570805

溶解性：DMSO ≥33mg/mL Water ≥121mg/mL Ethanol ≥2.6mg/mL

产品包装